Yoav Timsit
Blueprint Medicines (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Pharmacogenetics and Drug Metabolism, Growth Hormone and Insulin-like Growth Factors, Estrogen and related hormone effects
Most-Cited Works
- → CAR and PXR: The xenobiotic-sensing receptors☆(2006)419 cited
- → Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer(2022)154 cited
- → TRANSCRIPTIONAL SUPPRESSION OF CYTOCHROME P450 GENES BY ENDOGENOUS AND EXOGENOUS CHEMICALS(2004)97 cited
- → Coordinated Regulation of Nuclear Receptor CAR by CCRP/DNAJC7, HSP70 and the Ubiquitin-Proteasome System(2014)45 cited
- → The state of the art in secondary pharmacology and its impact on the safety of new medicines(2024)34 cited
- → Abstract 1262: BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC(2021)24 cited
- → Interference with Growth Hormone Stimulation of Hepatic Cytochrome P4502C11 Expression in Hypophysectomized Male Rats by 3-Methylcholanthrene(2000)20 cited
- → Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes(2019)20 cited
- → Non-monooxygenase cytochromes P450 as potential human autoantigens in anticonvulsant hypersensitivity reactions(1998)18 cited
- → The 2001 Veylien Henderson Award of the Society of Toxicology of Canada. Positive and negative transcriptional regulation of cytochromes P450 by polycyclic aromatic hydrocarbons(2003)17 cited